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single-center analysis. infectious diseases).
Background. Despite improvements in immunosuppressive In spite of these advances, grafts continue to fail. Inprotocols and patient care, kidney allografts continue to fail.
1991, we reviewed the causes of graft loss at our insti-We studied causes of graft loss for primary kidney transplants
tution in the 1980s versus the 1970s [1]. We noted thatin the 1990s to determine major causes and potential interven-
tions. graft loss to acute rejection and to infectious death had
Methods. Causes of graft loss were reviewed for 1467 pri- markedly decreased, but that chronic rejection and car-
mary kidney transplants done at our institution between Janu- diovascular death had become the major causes of graft
ary 1, 1990, and December 31, 1999. Graft loss for that entire loss. This observation led to clinical studies in which wepopulation was studied and then the causes of loss selectively
showed that an acute rejection episode is the major riskexamined at1 year, 1 to 5 years, and5 years post-transplant.
factor for biopsy-proven chronic rejection [2, 3], that theFinally, causes of loss in the 1990s versus the 1980s were com-
pared. incidence of early post-transplant acute rejection could
Results. Five major causes of graft loss were noted in the be reduced by maintaining higher immunosuppressive
1990s: thrombosis, acute rejection (either alone or combined drug levels [4, 5], and that a decreased incidence of
with delayed graft function or infection), chronic rejection, acute rejection is associated with a decreased incidencedeath with function, and noncompliance. In the first year post-
of chronic rejection [6].transplant, thrombosis (25%) and death with function (41%)
During the last ten years, patient care and immunosup-were the major causes of graft loss. After the first year, chronic
rejection and death with function predominated. For recipients pressive protocols have changed significantly. Numerous
dying with graft function, cardiovascular disease was the major new immunosuppressive agents have been approved for
cause of death. induction and maintenance therapy and for treatment
Conclusions. This study identified the five major causes of of rejection. However, because of improved transplantkidney graft loss in the 1990s. Different interventions are re-
outcome, acceptance criteria for transplant candidatesquired to decrease loss from each of these causes. Future re-
have been expanded. Older as well as higher-risk candi-search needs to be directed at such interventions.
dates are now being accepted.
For patients with end-stage renal disease (ESRD), a
transplant provides better survival rates and better qual-During the last four decades, both short- and long-
ity of life than dialysis [7–10]. Nonetheless, their expectedterm kidney allograft survival rates have significantly
life span is not yet similar to the age-matched general pop-improved, thanks to advances in immunosuppressive reg-
ulation. We asked what could be done to further improveimens and in the overall care of transplant recipients (in-
post-transplant clinical outcome, and reviewed causes ofcluding pretransplant cardiovascular screening, anesthe-
graft loss for recipients transplanted in the 1990s. Unique
to this analysis is that we studied causes of graft loss for
three intervals post-transplant (1 year, 1 to 5 years,51 See Editorial by Langone and Helderman, p. 718.
years) to determine whether causes and potential in-
Key words: organ rejection, kidney graft, allograft, transplantation, terventions differed.
thrombosis, delayed graft function, chronic rejection.
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(LD); 534 cadaver donor (CAD)] were done at the Uni- of an acute rejection episode was limited because of
concurrent infection. Graft loss due to acute rejectionversity of Minnesota. Immunosuppressive protocols have
been described in detail [11]. In brief, for most of the alone was studied first, and then graft loss due to acute
rejection combined with either DGF or infection.decade, adult LD recipients were treated with triple ther-
apy: cyclosporine (CsA); an antimetabolite [originally Graft loss to chronic rejection was defined by patho-
logic findings, on biopsy or at nephrectomy, that wereazathioprine (AZA) and then mycophenolate mofetil
(MMF)]; and prednisone (P). In 1999, we started using consistent with chronic rejection. The concept of defin-
ing death with function as graft loss originated with thea short course of antibody (Thymoglobulin) induction
for LD recipients. CAD recipients and all pediatric kid- recognition that many post-transplant deaths (with func-
tion) were due to infection secondary to the surgery andney recipients were treated with sequential therapy:
antibody induction (originally Minnesota ALG, then immunosuppressive regimens; more recently, it has been
noted that immunosuppression-related hypertension,ATGAM, and more recently Thymoglobulin); an anti-
metabolite (originally AZA, then MMF); P; and delayed hyperlipidemia, and diabetes affect post-transplant mor-
tality.introduction of CsA.
Pretransplant evaluation has been described in detail In addition, the incidence of graft loss to overt non-
compliance initially was determined, and then cases were[12]. Of note, at the time of evaluation, patients with di-
abetes or with a history of cardiovascular disease under- added of graft loss to acute or chronic rejection for which
we believed noncompliance played an important role.went stress tests and often cardiac angiography [13].
Mild-to-moderate acute rejection episodes were treated The patient and graft survival rates were calculated,
as well as graft loss rates due to specific causes, by usingwith a recycling of the steroid taper; steroid-resistant re-
jections were often treated initially with antibody. Severe actuarial techniques. Comparisons between decades were
made using a generalized Wilcoxon test.acute rejection episodes (that is, involving severe tubulo-
interstitial infiltrate or vascular rejection) were treated
with antibody. All acute rejection episodes were biopsy-
RESULTS
proven.
The average age ( SE) of recipients transplanted inAll recipients were treated with perioperative anti-
the 1990s was 41  0.5 years, which was significantlybiotics and then were maintained on long-term trimeth-
older than in the 1980s (33  0.4 years), 1970s (33  0.4oprim-sulfamethoxazole. Cytomegalovirus prophylaxis
years), or 1960s (30  0.1 years; P  0.01). Patient sur-consisted of acyclovir and/or ganciclovir. (Most recipi-
vival for primary recipients, by decade, is shown in Fig-ents were enrolled in trials comparing oral and intrave-
ure 1A. In spite of the increased average age of ournous regimens.)
transplant population, there was a stepwise increase inAll patient information was kept on a microcomputer
patient survival by decade. Graft survival for primarydatabase. The actuarial patient and graft survival rates
recipients, by decade and donor source, is shown in Fig-were calculated for primary kidney recipients trans-
ure 1B. Improvement by decade was significant (Ta-planted in the 1990s (N  1467) versus the 1960s (N 
ble 1). This improvement in graft survival also was seen149), 1970s (N  1011), and 1980s (N  1303).
for death-censored graft survival.For those transplanted in the 1990s, we determined
For primary recipients transplanted in the 1990s,causes of graft loss and causes of death. Graft loss was
causes of graft loss for LD and CAD kidneys are showndefined as return to chronic dialysis, retransplantation,
in Table 1. Acute rejection was a relatively rare cause ofgraft removal, or death of the recipient, whichever came
graft loss. The major causes of graft loss were death withfirst. First, causes of graft loss for the entire transplant
function and chronic rejection. Causes of graft loss (LDpopulation were studied, and then causes of loss were
and CAD combined) by time post-transplant (1 year,selectively studied 1 year, 1 to 5 years, and 5 years
1 to 5 years, 5 years) are shown in Table 2. When onlypost-transplant.
graft loss1 year post-transplant was considered, techni-Causes of graft loss in the 1990s versus the 1980s
cal failures or thromboses were responsible for 25% ofwere compared, focusing the analyses on the major
graft loss; death with function, 41%. After one year,causes of graft loss: perioperative thrombosis, acute re-
chronic rejection and death with function were the pre-jection, chronic rejection, noncompliance, and death
dominant causes of graft loss.with function.
Overt noncompliance (that is, the recipient unilater-In general, when 2 potential causes of graft loss oc-
ally discontinued medications) was the cause of 8% ofcurred, the cause of graft loss was assigned to the one
graft loss (LD and CAD combined) in the 1990s (Ta-deemed most significant. Although graft loss due to acute
ble 1). Noncompliance was responsible for 4% of graftrejection alone has been rare, there have been cases of
loss 1 year post-transplant; 11%, 5 to 10 years post-graft loss due to acute rejection superimposed on delayed
graft function (DGF) as well as cases where treatment transplant. However, many recipients whose chart lists
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Fig. 1. Primary kidney recipients: Patient and graft survival by decade. For LD, there was a significant stepwise improvement in patient survival
(A; 1970s vs. 1960s, P  0.3; 1980s vs. 1970s, P  0.0001; and 1990s vs. 1980s, P  0.0009) and in graft survival (B; 1970s vs. 1960s, P  0.08;
1980s vs. 1970s, P  0.0001; 1990s vs. 1980s, P  0.0001). For CAD, there was a significant stepwise improvement in patient survival (C; 1970s
vs. 1960s, P  .0001; 1980s vs. 1970s, P  0.0001; and 1990s vs. 1980s, P  0.1) and in graft survival (D; 1970s vs. 1960s, P  0001; 1980s vs. 1970s,
P  0.0001; and 1990s vs. 1980s, P  0.03).
other causes of graft loss had noncompliance as a contrib- malignancy were distributed throughout the post-trans-
uting factor (Table 3). When these cases were added plant course. Types of malignancy in our transplant pop-
into the total, noncompliance was responsible for at least ulation (by time post-transplant) are shown in Table 6.
10.5% of LD and 12.8% of CAD graft loss.
When graft loss rates due to specific causes in the
DISCUSSION1990s were compared to the 1980s (Fig. 2), we found that,
A successful kidney transplant (vs. long-term hemodi-in the 1990s, graft loss due to acute rejection significantly
alysis) provides improved longevity and significantly bet-decreased (P  0.001; Fig. 2A), as did graft loss due to
ter quality of life [7]. Both short- and long-term patientchronic rejection (P  0.003; Fig. 2C). A trend toward
and graft survival rates post-transplant have steadily im-decreased graft loss due to death with function (P 
proved in the last four decades. It is likely that improved0.055; Fig. 2D) was noted. No change was seen in graft
care early after transplantation has contributed to theloss due to acute rejection combined with DGF or infec-
improved long-term results [6]. However, some recipi-tion (Fig. 2B), thrombosis (Fig. 2E), or noncompliance
ents die as a consequence of the surgery and immunosup-(Fig. 2F).
pressive therapy, while others lose their graft and needCauses of death with function for primary LD and
to return to dialysis.CAD recipients are shown in Table 4. Cardiovascular dis-
In this current analysis of our primary kidney trans-ease was the predominant cause of death, followed by
plants in the 1990s, we identified five major and poten-infection and malignancy. Causes of death by time post-
tially preventable causes of graft loss: thrombosis, acutetransplant (LD and CAD combined) are shown in Ta-
rejection (either alone or combined with infection orble 5. Infectious deaths tended to occur early post-trans-
plant, whereas cardiovascular deaths and deaths due to DGF), chronic rejection, noncompliance, and death with
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Table 2. Causes of graft loss, by time post-transplantTable 1. Causes of graft loss for primary kidney recipients,
transplanted in the 1990s
1 year 1–5 years 5 years
(N  138) (N  163) (N  91)# Losses % Loss % Grafts
Living donor (LD) (N  181) (N  933)a Acute rejection 7% 0.5% —
Acute rejection and either infec-Death with function 81 45% 9.0%
Chronic rejection 39 23% 4.4% tion or delayed graft function 8% 1.8% —
Chronic rejection 6% 28% 25%Thrombosis 15 8.2% 1.6%
Discontinuation of medications 15 8.2% 1.6% Technical complications/
thrombosis 25% — —Acute rejection 7 3.0% 0.6%
Recurrence 8 4.4% 0.9% Discontinuation of medications 4% 9% 11%
Death with function 41% 52% 57%Acute rejection and infection 5 2.7% 0.5%
Unknown 4 2.2% 0.4%
Other 4 1.7% 0.3%
Pre-renal disease 3 1.7% 0.3%
De novo disease 1 0.5% 0.1%
Table 3. Causes of graft loss for noncompliant recipientsCadaver donor (CAD) (N  211) (N  534)b
Death with function 89 42% 1.6% Listed cause of loss CAD LD
Chronic rejection 43 20% 8.0%
Thrombosis 18 8.5% 3.3% Acute rejection 15% —
Chronic rejection 8% 5%Discontinuation of medications 17 8.1% 3.2%
Other 13 6.2% 2.4% Discontinuation of medications 17% 13%
Other 1% 1%Acute rejection and either infec-
tion or delayed graft function 8 3.8% 1.5% % Loss
Discontinuation of medications alone 8.1% 7.1%Acute rejection 4 1.9% 0.7%
Recurrence 4 1.9% 0.7% Discontinuation of medications plus
noncompliance 12.8% 10.5%De novo disease 4 1.9% 0.7%
Unknown 3 1.4% 0.6% Abbreviations are: CAD, cadaver donor; LD, living donor.
Pre-renal disease 2 1.0% 0.4%
a 751 (80.4%) grafts are currently functioning
b 323 (60%) grafts are currently functioning
Some thromboses are probably technical and could be
prevented by greater attention to technical detail during
surgery. However, other thromboses are due to a hyper-function. These five causes were responsible for 89% of
coagulable state that was not recognized at the time ofLD and 85% of CAD graft loss. Importantly, causes of
the transplant. A number of risk factors that predisposegraft loss were subdivided by time post-transplant. Doing
to a hypercoagulable state have recently been describedso allowed us to focus on the differences in graft loss
[17]. These risks seem additive, so patients with two oroccurring 1 year versus 1 post-transplant.
more risk factors are at markedly increased risk for graft
thrombosis or other thrombotic events.Thrombosis
The most common genetic risk factor for thrombosis
Thrombosis was responsible for 8% of graft loss (LD in adults is a single point mutation in the coagulation
and CAD combined). However, thrombosis was respon- factor V gene (termed Factor V Leiden mutation). The
sible for 25% of graft loss 1 year post-transplant. Oth- mutation, found in 3% to 7% of the general population,
ers also have noted a high rate of early (that is, 1 year) can be screened for by testing for resistance to inactiva-
graft loss due to thrombosis [14, 15]. Penny et al, in a tion by activated protein C. Importantly, surgery and
review of transplants done in Australia and New Zealand trauma are the most common risk factors for thrombosis
between 1980 and 1992, found that of the 816 graft fail- in carriers of the Factor V Leiden mutation [18]. In pa-
ures within 30 days, 117 (14.3%) were due to thrombosis tients without the mutation, resistance to activated pro-
[14]. More recently, Bakir et al reported that thrombosis tein C is an independent risk factor for thrombosis [18].
was responsible for 45% of graft loss 90 days and 37% Irish et al found a fourfold increased risk of renal vein
1 year [15]. Independent risk factors for thrombosis thrombosis in kidney recipients with the Factor V Leiden
were use of a donor right kidney (P  0.007), recipient mutation [19]. Others have reported additional cases. Of
past history of venous thrombosis (P  0.000), diabetic interest, kidney recipients with the mutation also have
nephropathy (P  0.000), technical surgical problems been noted to have an increased rate of early acute vas-
(P  0.000), and poor hemodynamic status peri- and cular rejection [20].
early postoperatively. Ojo et al also found prior perito- A number of antibodies, termed antiphospholipid an-
neal dialysis (vs. hemodialysis) to be a risk factor [16]. tibodies (APAs), occur in up to 5% of the general popu-
We saw no change in graft loss due to thrombosis in lation. They also may be found in patients with infection
the 1990s versus the 1980s. Thus, the proportion of graft or autoimmune diseases such as systemic lupus erythe-
loss in our and other series has likely increased as the matosus (SLE). Patients with APAs may have no detect-
able disease or may have the antiphospholipid syndromenumber of grafts lost to other causes has decreased.
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Fig. 2. Graft loss to specific causes in the 1990s versus 1980s. (A) Acute rejection; (B) acute rejection combined with delayed graft function (DGF)
or infection; (C ) chronic rejection; (D) death with function; (E ) thrombosis; and (F ) noncompliance.
(APS). Manifestations of APS include thromboembolic found in 57% of those with failure versus 35% of controls
(P 0.02). The presence of APAs was predictive of graftevents such as pulmonary emboli, deep vein thrombo-
phlebitis, thrombocytopenia, recurrent miscarriages, pul- failure for recipients undergoing preemptive transplants
(P  0.002) but not for those who had pretransplant di-monary hypertension, and Raynaud’s phenomenon [21].
The most commonly studied APAs are the anticardio- alysis (P  0.38). Similarly, Ducloux studied APAs in
kidney recipients without SLE [23]. Of 178 recipients,lipin antibodies and the lupus anticoagulant.
Wagenknecht et al tested for the presence of APAs 50 (28.1%) had APAs. The incidence of thrombosis was
significantly higher in recipients with antibodies.in 56 kidney recipients (without SLE) who had early graft
failure and 56 recipients with function [22]. APAs were Vaidya et al found elevated anticardiolipin antibodies
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Table 6. Post-transplant malignancyTable 4. Major causes of death with function for primary kidney
recipients, transplanted in the 1990s
Time post-transplant Type (recipient ages at transplant)
Living donors Cadaver donors
1 year Lymphoma (3, 15, 30)(LD) (CAD)
Pancreas (72)
Bladder (65)N % N %
1–2 years Lymphoma (55); breast (57)
Sepsis 2–5 years Brain (47)

Leukemia (50)
Viral 1 2
Bacterial 2 3 18.6% Lung (48, 65)
Fungal 4 14.4% 5 Lymphoma (63)
Mixed 2 6 Melanoma (57)
Other or unknown 2 Merkel cell (46)
Cardiovascular disease Nodal (72)
 Prostate (69)
Myocardial infarction 5 4
Other cardiac event 7 36.8% 13 47.6% Squamous (47, 47)
Cerebrovascular accident 4 6 5 years Colorectal (72, 66)
Sudden death at home 12 18 Lymphoma (51)
Malignancy 13 17% 12 11.6% Lung (49, 54, 60)a
Prostate (61)
a 2 small cell
Table 5. Causes of death with function, by time post-transplant
1 year 1–5 years 5 years
(N  49) (N  73) (N  40) additional 3% of LD and 4% of CAD grafts were lost
Sepsis to acute rejection combined with either DGF or infection
Viral 1 — — (thus limiting our ability to treat the rejection).
Bacterial 2 2 —
The incidence of acute rejection is increased in recipi-Fungal 4 2 1
Mixed 3 4 — ents with DGF [28]. For that reason, and because we did
Unknown 3 3 2 not want to introduce calcineurin inhibitors in our recipi-
Cardiovascular disease
ents until DGF began to resolve, most of our recipientsMyocardial infarction 2 2 5
Other cardiac event 5 7 8 with DGF received an extended course of polyclonal
Cerebrovascular accident 3 6 1 antibody. If DGF did not begin to resolve by seven to
Sudden death at home 8 16 6
ten days post-transplant, we did a percutaneous allograftMalignancy 5 12 8
biopsy. If rejection was identified, we usually switched to
a different antibody therapy (usually OKT3). However,
some kidneys never recovered from these dual insults.
Prolonged acute tubular necrosis (ATN) will ultimatelyin 93 (19%) of 502 kidney transplant candidates [24].
Of these, 23 had documented evidence of thrombotic result in fibrosis. In our transplant population, we still do
not know whether graft failure was due to the rejectiondisorders leading to the diagnosis of APS. Of the 23, 11
were transplanted: four with and seven without anticoag- resulting in prolongation of the ATN or whether a differ-
ent mechanism was involved. In most such cases, subse-ulation. All 7 without anticoagulation experienced graft
thrombosis post-transplant. quent biopsies showed resolution of rejection, but the
kidney never began to function.In kidney recipients with SLE, the presence of anti-
phospholipid antibodies at the time of the transplant The solution to this problem in the future is to prevent
both DGF and acute rejection. Risk factors for DGFalso increased the risk of graft loss due to thrombosis
and the risk of other thrombotic events [25, 26]. have been described [29, 30]. Most risk factors [for exam-
ple, donor race, donor and recipient age, recipient panelRecognition of these genetic factors and others associ-
ated with increased thrombosis [27] suggests that a screen- reactive antibody (PRA)] are fixed at the time of the
transplant. However, one important risk factor that ising panel should be developed for kidney transplant can-
didates. However, given the relative rarity of such events not fixed is cold ischemia time (CIT). A longer CIT is
associated with an increased incidence of DGF, and this(affecting 2% of grafts) and the costs of a screening
panel, the idea remains controversial. Some advocate effect is magnified when older donor kidneys are used
[31]. We have recently proposed a change in our alloca-screening for all candidates; others believe it should only
be done for those with a previous thrombosis or a family tion algorithm that could shorten CIT [32].
For kidney recipients with DGF, new immunosuppres-history of thrombosis.
sive protocols need to be devised to further lower the
Acute rejection acute rejection rate. Outcome for recipients with DGF
but no acute rejection is significantly better than forIn our series, acute rejection alone was responsible
for 3% of LD and 2% of CAD donor loss. However, an recipients with both DGF and acute rejection [28].
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Care of recipients with simultaneous acute rejection moted: considerable time for donor evaluation and selec-
and significant infection is a therapeutic dilemma. The pri- tion will help ensure that both donor and recipient are
ority needs to be the recipient and not the graft. There- in optimum condition at the time of nephrectomy. Of
fore, a rejection episode may be under-treated or not great importance are stringent LD selection criteria, a
treated at all, leading to graft failure. The obvious, but carefully developed informed consent process, and me-
often elusive, solution is to prevent both infection and ticulous operative and perioperative care.
acute rejection. Second, protocols should be developed to decrease
the acute rejection rate (which affects the Y intercept).
Chronic rejection/chronic allograft nephropathy Clinical studies have shown that decreased acute rejec-
In our series, chronic rejection was responsible for 23% tion is associated with decreased biopsy-proven chronic
of LD and 20% of CAD graft loss. The pathogenesis of rejection [6].
chronic rejection remains controversial and two major Third, for CAD recipients, every effort also must be
hypotheses are still debated [33]. The first hypothesis made to maximize the initial GFR. Research must con-
is that chronic rejection is an immunologic process. In tinue on ways to improve donor care and organ preserva-
support of this hypothesis is a body of data suggesting tion. In addition, CIT must be minimized, so as to mini-
that (a) the major risk factor for biopsy-proven chronic mize preservation damage. As described above, studies
rejection is a previous acute rejection episode [2, 3, 34] have shown an increased incidence of DGF with in-
and (b) decreasing the acute rejection rate will decrease creased CIT, an effect that is magnified with older donor
the chronic rejection rate [6, 35]. In fact, recent data kidneys. As well, DGF is associated with an increased
have suggested that many recipients with normal kidney incidence of rejection. We recently showed that this in-
function have subclinical rejection according to protocol creased risk also applies to recipients whose grafts regain
biopsies [36]. In a prospective randomized study, Rush function slowly (but who do not require post-transplant
et al showed that, when compared with recipients not dialysis), a process we defined as slow graft function
having protocol biopsies, those having biopsies and being (SGF) [43]. Similarly, it would be possible, although dif-
treated for subclinical rejection had lower two-year se- ficult, to develop allocation algorithms to match initial
rum creatinine levels [37]. nephron mass to the recipient’s body size.
The second hypothesis is that the process is due to Finally, consideration should be given to using “neph-
transplantation of a limited nephron mass in relation to roprotective” blood pressure medications. In prospective
the recipient’s metabolic needs (a nonimmunologic pro- randomized trials, angiotensin-converting enzyme (ACE)
cess); the resulting hyperfiltration of the remaining neph- inhibitors have been shown to slow deterioration of kid-
rons causes additional nephron damage. In support of
ney function in non-transplant patients with type 1 and
this hypothesis is a body of data suggesting that trans-
type 2 diabetic and nondiabetic nephropathy [44–48].plantation of kidneys with presumed limited nephron
A similar effect has been shown for an angiotensin-II-mass in relation to the recipient’s needs (for example,
receptor antagonist in non-transplant patients with typeuse of kidneys from older donors or from African Ameri-
2 diabetes [49]. In kidney transplant recipients, single-cans, or use of female donor kidneys in male recipients)
center studies have shown decreased proteinuria andis associated with worse outcome [38–42]. Proponents of
better microvascular function after treatment with ACEthis hypothesis refer to “chronic allograft nephropathy”
inhibitors [50–52]. However, one double-blind prospec-rather than chronic rejection. Clearly, these two hypoth-
tive randomized study found better kidney graft functioneses are not mutually exclusive. An acute rejection epi-
at two years post-transplant in recipients treated withsode may result in nephron damage, thus causing hyper-
nifedipine (vs. lisinopril) [53].filtration.
Recently, Hunsicker et al proposed a concept that Noncompliance
unites these two hypotheses (abstract; Transplantation
In our series, noncompliance was responsible for 8%67:583, 1999). They suggested that, post-transplant, all
of LD and CAD graft loss (Table 1). In addition, non-kidneys lose function at a slow but steady rate, that is,
compliance contributed to the loss of other grafts (Ta-the plot of glomerular filtration rate (GFR) versus time
ble 3). Gaston et al evaluated the role of noncomplianceis a straight line with a negative slope. If true, initial
in graft loss in their series [54]. Between 1992 and 1995,GFR (Y intercept of the plot of GFR vs. time) is critically
a total of 1005 recipients had graft survival 6 months.important. Hunsicker et al suggested that this Y intercept
Of these 1005 recipients, 184 subsequently lost theiris affected by both immunologic and nonimmunologic
grafts over the ensuing 48  11 months. Although graftevents.
loss was often initially attributed to acute or chronicWhat can be done to decrease graft loss due to these
rejection, a chart review found that 64 (35%) of theevents? First and foremost, the initial GFR must be max-
imized. We believe that LD transplants should be pro- losses were, in fact, due to noncompliance. Gaston et al
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concluded that noncompliance was the primary cause of an increasingly common cause of graft loss. In light of this
aging of the transplant population, Gjertson et al askedgraft loss at their center.
Theoretically, the rate of graft loss due to noncompli- what percent of post-transplant deaths could be attrib-
uted to the surgery and immunosuppressive medicationsance could be reduced by careful recipient selection.
However, it is difficult to predict which recipients will be versus the number expected in the non-transplant popu-
lation [59]. They noted that, for CAD kidney recipients,noncompliant [55]. We, like others, would not transplant
candidates who are noncompliant with their dialysis regi- death rates were about five times greater than in the
age-matched general U.S. population. However, survivalmen. Under such circumstances, we would insist on a
minimum of 6 to 12 months in which compliance is clearly after a transplant was significantly better than on hemo-
dialysis. Until recently, it was not clear whether thisdemonstrated, before even considering a transplant.
Some authors have suggested that all transplant candi- discrepancy was due to recipient selection. Recent stud-
ies compared outcome for patients accepted for a trans-dates undergo a period of pretransplant hemodialysis in
order to learn the difficulties of dialysis and thereby plant but still on the waiting list versus those accepted
and subsequently transplanted [7–9]. The transplantedpossibly improve post-transplant compliance. However,
we have found that noncompliance is not increased in patients had significantly better survival. Survival post-
transplant is inversely related to the number of years ofrecipients of preemptive transplants [56].
In addition to careful recipient selection, a post-trans- pretransplant dialysis [10, 60].
Our current study (Tables 4 and 5) and that of Ojoplant test perhaps could be developed to help predict,
prevent, or treat noncompliance. However, drug level et al [58] showed that cardiovascular events are the most
common cause of death with function. Kidney transplantmonitoring has not been useful for prediction of noncom-
pliance; nor have pill counts. At our institution, Nevins recipients are at markedly increased risk for cardiovascu-
lar disease for numerous reasons. For many recipientset al recently studied the use of a computer chip in the
capsule of the azathioprine pill bottle (MEMS) to moni- (for example, those with diabetes or hypertension), their
primary disease itself is associated with increased cardio-tor medication usage [57]. One assumption of their study
was that compliance in taking azathioprine was associ- vascular risk. Other recipients develop hypertension, hy-
perlipidemia, and hyperhomocysteinemia in associationated with compliance in taking all of the other immuno-
suppressive medications. In their series, a subset of kid- with kidney failure. Excess risk also may be due to the
hemodynamic and metabolic factors that occurred dur-ney recipients had declining compliance in the first three
months post-transplant that was associated with an in- ing the pretransplant interval of chronic renal insuffi-
ciency (such as anemia, proteinuria, increased extracellu-creased incidence of acute rejection episodes and an
increased graft loss rate. Thus, MEMS can be used to lar volume, electrolyte imbalance, and higher levels of
thrombogenic factors) [61]. Non-transplant patients withidentify recipients who are noncompliant. It remains to
be seen whether intervention can increase compliance ESRD are at increased risk for mitral and aortic valve
calcification, as well as for coronary artery calcificationand decrease graft loss.
[62]. Post-transplant hyperlipidemia, diabetes, and hy-
Death with function pertension related to immunosuppressive regimens con-
tinue to place kidney recipients at increased risk [63–65].In our series, death with function was responsible for
45% of LD and 42% of CAD graft loss (Table 1). Clearly, We believe cardiovascular deaths could be reduced
by a combination of interventions. First, more aggressivethe goal of all transplant programs is to have recipients
die with function, albeit at an age comparable to deaths blood pressure and lipid control is crucial for transplant
candidates with incipient kidney failure and for those onin the general population. Yet, in our series, death with
function accounted for 40% of graft loss 1 year post- dialysis. Candidates must be encouraged to stop smok-
ing; in fact, transplant centers should consider not trans-transplant and 50% by 10 years post-transplant. Ojo
et al analyzed United Network for Organ Sharing (UNOS) planting anyone who continues to smoke. Smoking has
a significant negative effect on post-transplant patientand United States Renal Data System (USRDS) data
and similarly noted that death with function was respon- survival [66].
Second, preemptive transplants should be done when-sible for 42.5% of graft loss for recipients transplanted
between 1988 and 1997 [58]. Importantly, most of these ever possible. Cosio et al showed better survival in recipi-
ents of preemptive transplants (vs. those who underwentpremature deaths occurred in recipients with normal
graft function. pretransplant dialysis) [67]. They noted that increasing
time on dialysis significantly increased the prevalence ofIn the 1970s, patients over the age of 50 were consid-
ered to be high-risk transplant candidates. Currently, both left ventricular hypertrophy and cardiomegaly. As
described earlier, length of time on dialysis has beenpatients in their 60s and early 70s are routinely accepted
as transplant candidates. As the average age of the recipi- correlated with incidence and severity of cardiovascular
disease [61, 62]. Meier-Kriesche et al, using a multicenterent pool increases, death with function will likely become
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registry, confirmed the association between waiting time ade has brought increased understanding of the patho-
genesis and categorization of lymphoproliferative tu-and increased post-transplant mortality [10]. In their
analysis, the best post-transplant patient survival rates mors [70]. In addition, transplantation of organs from
Epstein-Barr virus (EBV)-positive donors into EBV-occurred in recipients with preemptive transplants. Wait-
ing times (on dialysis) of 6 to 12 months, 12 to 24 months, negative recipients has been identified as a risk factor.
Studies are now underway to determine whether or not24 to 36 months, 36 to 48 months, and 48 months were
associated with an increased post-transplant mortality risk therapy based on increased EBV viral load [vs. deter-
mined by whole blood polymerase chain reaction (PCR)]of 21%, 28%, 41%, 53%, and 72%, respectively [10].
Third, CAD candidates should undergo periodic re- will decrease the incidence of PTLD. New treatment
regimens are being studied.evaluation while on the waiting list. Most centers do a
thorough initial evaluation of transplant candidates, In summary, our study identifies five preventable prob-
lems responsible for the majority of graft loss in ourwhich may be sufficient for LD candidates. But CAD
candidates will likely wait three to five years before being kidney recipients transplanted in the 1990s. The graft
loss rate for acute and chronic rejection was significantlytransplanted. Even with an aggressive evaluation at the
time of the transplant, 6% of our CAD recipients had lower in the 1990s than the 1980s (P  0.003). We note
a trend toward a lower graft loss rate due to death witha perioperative (30 days) cardiac complication [68]. Our
data and the relatively high rate of early death with function (P  0.055); however, no change is seen in the
graft loss rate due to thrombosis or noncompliance. Eachfunction suggest that high-risk candidates must be rou-
tinely evaluated. If cardiovascular disease is identified, of these five causes of graft loss needs to be addressed
to improve outcome for future transplant recipients.it must be treated. Manske et al, in a prospective random-
ized study at our institution, showed that surgical inter-
vention was superior to medical management for diabetic ACKNOWLEDGMENTS
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with worse long-term outcome [63–65].
Fifth, kidney recipients should undergo routine post-
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